Senseonics: The Year-Long Sensor Finally Gets a Commercial Flywheel
A third guidance raise and a second pump partner turn the story from promise to print — but Europe and cash burn are the tell.
SENS · Earnings Call · 2026-11-09
From promise to print
Senseonics has spent years selling an implantable CGM story that sounded better in slides than in the P&L. The third quarter is the first where the commercial flywheel shows up in the numbers. Revenue hit $19.6 million, up about 140% year over year, with U.S. revenue of $16.8 million up roughly 160% and OUS revenue of $2.8 million up about 65%. Management raised full-year guidance to $68 million to $70 million from $62 million to $66 million — the third raise this year. “Q3 was a breakout quarter for Senseonics. Revenue reached $19.6 million, up about 140%, well more than double the prior year.” — Tim Goodnow, Chief Executive Officer · 2026-11-09 The Q2 filing already showed the turn: revenue was $14 million, up 118% year over year, with gross margin at 59.1%. Q3 simply extends that curve and lifts gross margin to about 62% from 43% a year ago. The margin trajectory is the clearest proof that in-housing the commercial organization was not just a cost story. The quarter’s top keyword is Beta Bionics, the second pump partner. The iLet Bionic Pancreas launch is expected in the coming weeks, with first patients possible before year-end and incremental growth in 2027. This is a real change, not just repetition. In May, Tim Goodnow was still saying “we continue to be very active. We don't have anything to announce, but it is an important focus for us, and we're continuing to make progress.” — Tim Goodnow, CEO · 2026-05-08 In March, when asked about additional pump partners, he said “we have not, as of yet, modeled additional pump companies in. We would look for that to be upsides, but still not announcing timing on the next one yet.” — Tim Goodnow, Chief Executive Officer (CEO) · 2026-03-02 Now they have two. Brian Hansen’s team has a blueprint: “the second launch is going to be easier than the first as we launch that here in the coming week or so, we think we have a fairly good blueprint for it.” — Brian Hansen, Chief Commercial Officer · 2026-11-09 But the company still will not quantify the twiist contribution, saying only that it helps retention. The pump thesis is validated on partner count, not on disclosed revenue. That is why pump compatibility and pump company matter: compatibility was a reason patients left, and two partners widen the funnel without changing the single sensor value proposition. Nine of ten new insertions are switchers from competitive sensors, active prescribers are up over 90%, and EON Care has already passed 100 inserters and is doing more than 40% of U.S. insertions. The Healthcare provider channel is finally getting easier to work with.The less durable parts of the beat
Gross margin deserves a closer look. Q3’s 62% was helped by a bundled-pay mix of about 65% versus the usual 60-40 split. The CFO called it a small shift and expects the mix to normalize: “We expect that bundled pay DME split to be back to 60-40. That's what we're forecasting for the fourth quarter. We don't think it's going to have any impact on our margins because at the same time, we'll have our 365 in Europe for the full quarter.” — Frederick Sullivan, Chief Financial Officer · 2026-11-09 The nuance is that Q4 margins hold only because Europe 365 and lower patient assistance offset the channel mix, not because the Q3 mix is permanent. The margin beat is real, but part of it is a mix tailwind that fades. Europe is the other soft spot. Full-year Europe is now expected to be about 15% of revenue, down from 20% previously. “We now expect Europe to represent approximately 15% of our full year revenue, down from the 20% we had previously discussed. That shift is a function of U.S. outperformance.” — Frederick Sullivan, Chief Financial Officer · 2026-11-09 That is partly true, but the analyst math implied absolute international dollars are also lower, not just the percentage. In March, Rick Sullivan had said “we do expect Europe to be about 20% of our revenue in 2026.” — Frederick Sullivan, Chief Financial Officer (CFO) · 2026-03-02 The company now says the transition took longer and the 365 launch in Europe came later. The U.S. is carrying the raise; Europe is a delayed launch, not a disaster, but it is a hidden miss. Retention is the third variable. Tim says about 94% of patients go all the way to full term, but the early drop-off is unchanged: first-to-second is about 75%, second-to-third about 85%. “We see about 94% of the folks go all the way to the full term... people on their first sensor about 75% of the time go on to the second. Second to third is about 85% of the time.” — Tim Goodnow, Chief Executive Officer · 2026-11-09 That is the same cadence management gave in May: “The historical has been first to second is around 75%, second to third is around 85%. By the time you get to your third sensor, it's well into the 90s.” — Tim Goodnow, CEO · 2026-05-08 So there is no evidence yet that 365 improves the first-year churn that determines reorder revenue. The install base is on track to double in the U.S., but the first-year drop remains the hinge.The cash clock and the 2028 promise
The CFO gave the line of the call:That is a strong statement. But the balance sheet is the constraint. Cash, restricted cash and short-term investments were $126.6 million at quarter-end, against $56.2 million carrying value of Hercules debt and $55 million principal. Full-year cash utilization is expected at the high end of the prior range, or about $120 million. Breakeven is expected shortly after the Freedom launch, which is targeted for 2028; first-in-human testing began October 26, and the pivotal study is planned for 2027. That means the company must fund 2027 and most of 2028 before the product that is supposed to drive breakeven reaches the market. The Q2 balance sheet looked more comfortable, with effective net cash of $180 million, but that was before the Q3 cash outlay. Free cash flow less stock comp was negative $34 million in Q2, and the Q3 TSA cash outlay made the burn heavier. R&D was $12 million in Q2, and Q3 R&D was $11.7 million. Management points to additional capacity under Hercules, which may bridge the gap, but this remains a financing story until Freedom launches. Valuation already reflects some of the recovery: price to revenue was 6.2x on Q2 numbers, and the market cap is about $518 million. On a $100 million 2027 revenue base, that is roughly 5x sales — not demanding if margins scale, but not a deep-value cushion either. The stock is up 54.6% in the last 90 days, yet still down 91% from its 2021 peak. The tape has voted for the inflection, but the report now has to sustain it. The global keyword map is dominated by tariff refunds and AI data centers; SENS is almost entirely company-specific. That purity is attractive, but it also means no macro tailwind will bail out a slip.We're going to give more formal guidance at the beginning of 2027, but we'll certainly be a $100 million company next year.